BioNTech
Founded Year
2008Stage
PIPE - II | IPOTotal Raised
$771.5MMarket Cap
21.74BStock Price
89.50Revenue
$0000About BioNTech
BioNTech (BNTX) focuses on the development of individualized immunotherapies for the treatment of cancer and infectious diseases within the biotechnology sector. The company's main offerings include mRNA therapeutics, engineered cell therapies, and a suite of antibody and small molecule immunomodulators designed for precision medicine. BioNTech's products are aimed at harnessing the power of the immune system to fight serious illnesses. It was founded in 2008 and is based in Mainz, Germany.
Loading...
Loading...
Research containing BioNTech
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned BioNTech in 3 CB Insights research briefs, most recently on Dec 11, 2024.
BioNTech Patents
BioNTech has filed 292 patents.
The 3 most popular patent topics include:
- clusters of differentiation
- immunology
- immune system
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
10/5/2021 | 3/25/2025 | Immunology, Immune system, Clusters of differentiation, Biotechnology, Transcription factors | Grant |
Application Date | 10/5/2021 |
|---|---|
Grant Date | 3/25/2025 |
Title | |
Related Topics | Immunology, Immune system, Clusters of differentiation, Biotechnology, Transcription factors |
Status | Grant |
Latest BioNTech News
Mar 26, 2025
'백신 호황' 끝난 바이오엔테크, 차세대 항암제로 새 성장판 여나 글자크기 조절 신약만 30개…임상3상 호재도 모건스탠리, 목표가 160弗 제시 코로나19 팬데믹 당시 화이자와 함께 메신저리보핵산(mRNA) 백신을 개발해 주목받은 독일 바이오테크 기업 바이오엔테크(BNTX)가 새로운 성장 국면에 접어들고 있다. 백신 수요 감소로 매출 부진을 겪고 있지만 mRNA 기술을 활용해 차세대 항암제 및 감염병 치료제 개발에 박차를 가해 다시 주목받고 있다. 바이오엔테크가 최근 발표한 지난해 4분기 실적에 따르면 매출은 12억달러로 전년 동기 대비 45% 감소했지만 시장 추정치(10억5000만달러)를 웃돌았다. 순이익은 2억4000만달러로 전년 동기 대비 50% 줄어들었다. 회사 측은 “백신 매출 감소는 불가피하지만 차세대 백신 및 항암제 연구개발(R&D) 투자 확대로 미래 성장 기반을 구축 중”이라고 설명했다. 바이오엔테크는 코로나19 백신 개발로 축적한 mRNA 기술을 활용해 차세대 항암제와 감염병 치료제 시장 진출을 본격화하고 있다. 30개 이상의 신약 파이프라인을 보유했고 일부는 임상 3상에 진입했다. 환자 개개인의 종양 특성을 분석해 맞춤형 mRNA 백신을 제작하는 방식으로, 면역 반응을 극대화할 수 있다. 월가 애널리스트들은 바이오엔테크가 내년부터 본격적인 성과를 낼 것으로 전망했다. 모건스탠리는 최근 보고서에서 “바이오엔테크의 항암제 파이프라인이 본격적으로 임상 3상에 진입하는 내년이 회사의 핵심 성장 모멘텀이 될 것”이라며 목표 주가를 140달러에서 160달러로 상향 조정했다. 현재 바이오엔텍 주가는 97.5달러로 100달러 밑으로 내려앉았다. 바이오엔테크가 직면한 가장 큰 리스크는 미국 식품의약국(FDA) 승인 과정이다. 개발 중인 항암 백신 및 감염병 치료제들이 임상을 통과하더라도 규제당국의 승인 절차가 까다로울 수 있기 때문이다. UBS는 “규제 리스크 및 경쟁 심화를 감안할 때 단기적으로 주가 변동성이 클 수 있다”고 평가했다. 이소현 기자 y2eonlee@hankyung.com 2 3
BioNTech Frequently Asked Questions (FAQ)
When was BioNTech founded?
BioNTech was founded in 2008.
Where is BioNTech's headquarters?
BioNTech's headquarters is located at An der Goldgrube 12, Mainz.
What is BioNTech's latest funding round?
BioNTech's latest funding round is PIPE - II.
How much did BioNTech raise?
BioNTech raised a total of $771.5M.
Who are the investors of BioNTech?
Investors of BioNTech include Coalition for Epidemic Preparedness Innovations, Temasek, Bill & Melinda Gates Foundation, Sanofi, Redmile Group and 9 more.
Who are BioNTech's competitors?
Competitors of BioNTech include Ethris and 2 more.
Loading...
Compare BioNTech to Competitors
Inscripta is a digital genome engineering company that focuses on the biomanufacturing sector. The company offers a platform and tools for optimizing strains in bioengineering processes, utilizing technologies such as Directed Evolution, CRISPR, and Machine Learning. Inscripta's services cater to the biotechnology and bioeconomy sectors, aiming to enhance biomanufacturing scalability and cost-effectiveness. Inscripta was formerly known as Muse Biotechnology. It was founded in 2015 and is based in Pleasanton, California.
Mammoth Biosciences is a biotechnology company that specializes in the development of in vivo gene editing therapeutics and diagnostics using CRISPR technology. The company offers a range of services, including precision gene editing with novel CRISPR-Cas enzymes, protein discovery and engineering, and a revolutionary molecular diagnostics platform. Mammoth Biosciences primarily serves the healthcare sector, with a focus on genetic medicine and collaborations with pharmaceutical companies. Mammoth Biosciences was formerly known as Apheleia Diagnostics. It was founded in 2017 and is based in Brisbane, California.
Alia Therapeutics focuses on developing gene-editing medicines within the biotechnology sector. The company specializes in creating therapies that correct genetic errors in patients' cells to treat rare genetic diseases. Alia Therapeutics' core technologies enhance the precision of genetic modifications It was founded in 2018 and is based in Milan, Italy.
ReCode Therapeutics operates as a genetic medicines company in the biotechnology industry. The company's main services include the development of mRNA and gene correction therapeutics, utilizing their selective organ targeting (SORT) lipid nanoparticle (LNP) platform. Its platform enables highly targeted delivery of genetic medicines to organs, tissues, and cells beyond the liver. It was founded in 2015 and is based in Menlo Park, California.
Ethris develops messenger ribonucleic acid (mRNA) therapeutics with a focus on respiratory diseases and vaccines. The technology platform helps enable the discovery, design, and development of transcript therapies that assist in restoring missing functions in patients' cells and tissues. It was founded in 2009 and is based in Planegg, Germany.
HDT Bio is a clinical stage biotechnology company focused on developing advanced RNA vaccine products for infectious diseases and cancers. The company's main offerings include a proprietary LION™ technology and self-amplifying RNA (repRNA) vaccines designed to activate the immune system and provide enhanced safety, potency, and durability. It was founded in 2018 and is based in Seattle, Washington.
Loading...